Interim results from a Phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma Meeting Abstract

  

Authors:	Herrera, A. F.; Moskowitz, A. J.; Bartlett, N. L.; Vose, J. M.; Ramchandren, R.; Feldman, T. A.; Lacasce, A. S.; Ansell, S. M.; Moskowitz, C. H.; Fenton, K.; Ogden, C.; Taft, D.; Zhang, Q.; Kato, K.; Campbell, M.; Advani, R. H.
Abstract Title:	Interim results from a Phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Meeting Title:	14th International Conference on Malignant Lymphoma
Journal Title:	Hematological Oncology
Volume:	35
Issue:	Suppl. 2
Meeting Dates:	2017 Jun 14-17
Meeting Location:	Lugano, Switzerland
ISSN:	0278-0232
Publisher:	Wiley Blackwell
Date Published:	2017-06-07
Start Page:	85
End Page:	86
Language:	English
ACCESSION:	123459974
DOI:	10.1002/hon.2437_73
PROVIDER:	EBSCOhost
PROVIDER:	cin20
DOI/URL:	http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=123459974&site=ehost-live
Notes:	Meeting Abstract: 74 -- Accession Number: 123459974 -- Entry Date: In Process -- Revision Date: 20170608 -- Publication Type: Article -- Supplement Title: Jun2017 Supplement -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20

https://synapse.mskcc.org/synapse/works/has_related_data_chk/112962